Kyiv Investment Group to spend $50 million in Russian blood preparations and recombinant drugs production

Kyiv Investment Group, one of Ukraine’s largest investment groups, has announced its plans to invest up to $50 million in the building of a plant for the production of blood preparations and recombinant drugs in Russia’s Kaluga region.

The new plant, the planned capacity of which was not disclosed, will be built in the Vorsino industrial park.

Russian analysts believe that the project can bring significant profits, as, according to DSM Group, one of Russia’s largest analyst agencies in the field of pharmaceutics, sales of immunoglobulin preparations in Russia are steadily growing and last year amounted to about 2.5 billion roubles ($76.66 million).